-
EP2930184
European procedure
Extract from the Register of European Patents
EP About this file: EP2930184
| EP2930184 - DKK-1 ANTIBODIES [Right-click to bookmark this link] | Status | No opposition filed within time limit Status updated on 07.02.2020 Database last updated on 01.04.2026 | |
| Former | The patent has been granted Status updated on 22.02.2019 | ||
| Former | Grant of patent is intended Status updated on 24.10.2018 | ||
| Former | Examination is in progress Status updated on 18.11.2016 | Most recent event Tooltip | 07.02.2020 | No opposition filed within time limit | published on 11.03.2020 [2020/11] | Applicant(s) | For all designated states Eli Lilly and Company Lilly Corporate Center Indianapolis, IN 46285 / US | [2015/42] | Inventor(s) | 01 /
Chedid, Marcio Lilly Corporate Centre Indianapolis, IN 46285 / US | 02 /
Darling, Ryan James Lilly Corporate Center Indianapolis, IN 46285 / US | 03 /
Galvin, Rachelle Jeanette Lilly Corporate Center Indianapolis, IN 46285 / US | 04 /
Swanson, Barbara Anne Lilly Corporate Center Indianapolis, IN 46285 / US | [2015/42] | Representative(s) | Kent, Lindsey Ruth, et al Eli Lilly and Company Limited 8 Arlington Square West Downshire Way Bracknell, Berkshire RG12 1PU / GB | [N/P] |
| Former [2015/42] | Kent, Lindsey Ruth, et al Eli Lilly and Company Limited Lilly Research Center Erl Wood Manor Sunninghill Road, Windlesham Surrey GU20 6PH / GB | Application number, filing date | 15159780.4 | 06.04.2010 | [2015/42] | Priority number, date | US20090168411P | 10.04.2009 Original published format: US 168411 P | [2015/42] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | EP2930184 | Date: | 14.10.2015 | Language: | EN | [2015/42] | Type: | B1 Patent specification | No.: | EP2930184 | Date: | 27.03.2019 | Language: | EN | [2019/13] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 03.07.2015 | Classification | IPC: | C07K16/18, A61K39/00 | [2015/42] | CPC: |
C07K16/18 (EP,KR,US);
A61K39/395 (KR);
A61K40/00 (KR);
A61P19/00 (EP);
A61P19/08 (EP);
A61P35/00 (EP);
A61P35/04 (EP);
A61K2039/505 (EP,KR,US);
A61K2039/585 (KR);
C07K2317/56 (EP,US);
C07K2317/565 (EP,KR,US);
C07K2317/73 (EP,KR,US);
| Designated contracting states | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR [2016/21] |
| Former [2015/42] | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR | Extension states | AL | 14.04.2016 | BA | 14.04.2016 | ME | 14.04.2016 | RS | 14.04.2016 | Title | German: | DKK-1-ANTIKÖRPER | [2015/42] | English: | DKK-1 ANTIBODIES | [2015/42] | French: | ANTICORPS CONTRE DKK-1 | [2015/42] | Examination procedure | 14.04.2016 | Examination requested [2016/21] | 18.04.2016 | Amendment by applicant (claims and/or description) | 04.05.2016 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report not received in time | 18.11.2016 | Despatch of a communication from the examining division (Time limit: M06) | 26.05.2017 | Reply to a communication from the examining division | 08.09.2017 | Despatch of a communication from the examining division (Time limit: M06) | 08.03.2018 | Reply to a communication from the examining division | 25.10.2018 | Communication of intention to grant the patent | 11.02.2019 | Fee for grant paid | 11.02.2019 | Fee for publishing/printing paid | 11.02.2019 | Receipt of the translation of the claim(s) | Parent application(s) Tooltip | EP10712681.5 / EP2417158 | Divisional application(s) | EP19156509.2 / EP3514173 | Opposition(s) | 03.01.2020 | No opposition filed within time limit [2020/11] | Request for further processing for: | The application is deemed to be withdrawn due to failure to reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report/Supplementary European search report | 18.04.2016 | Request for further processing filed | 18.04.2016 | Full payment received (date of receipt of payment) Request granted | 17.05.2016 | Decision despatched | Fees paid | Renewal fee | 20.07.2015 | Renewal fee patent year 03 | 20.07.2015 | Renewal fee patent year 04 | 20.07.2015 | Renewal fee patent year 05 | 20.07.2015 | Renewal fee patent year 06 | 02.05.2016 | Renewal fee patent year 07 | 02.05.2017 | Renewal fee patent year 08 | 30.04.2018 | Renewal fee patent year 09 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | SM | 27.03.2019 | [2019/52] | Documents cited: | Search | [I] WO2007084344 (NOVARTIS AG et al.) | [A] WO2008097510 (MERCK & CO INC et al.) | [A] WO2006015373 (AMGEN INC et al.) | [T] FULCINITI MARIATERESA ET AL: "Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, UNITED STATES LNKD- DOI:10.1182/BLOOD-2008-11-191577, vol. 114, no. 2, 9 July 2009 (2009-07-09), pages 371 - 379, XP009134332, ISSN: 1528-0020, [retrieved on 20090505] DOI: http://dx.doi.org/10.1182/blood-2008-11-191577 | [AP] GAVRIATOPOULOU MARIA ET AL: "Dickkopf-1: a suitable target for the management of myeloma bone disease.", EXPERT OPINION ON THERAPEUTIC TARGETS JUL 2009 LNKD- PUBMED:19530987, vol. 13, no. 7, July 2009 (2009-07-01), pages 839 - 848, XP009134320, ISSN: 1744-7631 | [A] YACCOBY SHMUEL ET AL: "Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US LNKD- DOI:10.1182/BLOOD-2006-09-047712, vol. 109, no. 5, 1 March 2007 (2007-03-01), pages 2106 - 2111, XP002486200, ISSN: 0006-4971, [retrieved on 20061026] DOI: http://dx.doi.org/10.1182/blood-2006-09-047712 | [A] ETTENBERG SETH A ET AL: "BHQ880, a novel anti-DKK1 neutralizing antibody, inhibits tumor-induced osteolytic bone disease", PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, NEW YORK, NY, US, vol. 49, 1 April 2008 (2008-04-01), pages 947, XP009134334, ISSN: 0197-016X | [A] HEATH DEBORAH J ET AL: "Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma", JOURNAL OF BONE AND MINERAL RESEARCH, AMERICAN SOCIETY FOR BONE AND MINERAL RESEARCH, NEW YORK, NY, US LNKD- DOI:10.1359/JBMR.081104, vol. 24, no. 3, 1 March 2009 (2009-03-01), pages 425 - 436, XP009134333, ISSN: 0884-0431, [retrieved on 20091204] DOI: http://dx.doi.org/10.1359/jbmr.081104 | [A] FILIPPO CARACI ET AL: "The Wnt Antagonist, Dickkopf-1, as a Target for the Treatment of Neurodegenerative Disorders", NEUROCHEMICAL RESEARCH, KLUWER ACADEMIC PUBLISHERS-PLENUM PUBLISHERS, NE LNKD- DOI:10.1007/S11064-008-9710-0, vol. 33, no. 12, 22 April 2008 (2008-04-22), pages 2401 - 2406, XP019647587, ISSN: 1573-6903 DOI: http://dx.doi.org/10.1007/s11064-008-9710-0 | [A] HALL CHRISTOPHER L ET AL: "Dickkopf-1 expression increases early in prostate cancer development and decreases during progression from primary tumor to metastasis", PROSTATE, WILEY-LISS, NEW YORK, NY, US LNKD- DOI:10.1002/PROS.20805, vol. 68, no. 13, 15 September 2008 (2008-09-15), pages 1396 - 1404, XP009134318, ISSN: 0270-4137, [retrieved on 20080616] DOI: http://dx.doi.org/10.1002/pros.20805 | [A] TERPOS E: "Antibodies to dickkopf-1 protein", EXPERT OPINION ON THERAPEUTIC PATENTS, INFORMA HEALTHCARE, GB LNKD- DOI:10.1517/13543776.16.10.1453, vol. 16, no. 10, 1 October 2006 (2006-10-01), pages 1453 - 1458, XP002486202, ISSN: 1354-3776 DOI: http://dx.doi.org/10.1517/13543776.16.10.1453 | [AP] ZHOU XIAO-LEI ET AL: "Downregulation of Dickkopf-1 is responsible for high proliferation of breast cancer cells via losing control of Wnt/beta-catenin signaling", ACTA PHARMACOLOGICA SINICA, vol. 31, no. 2, February 2010 (2010-02-01), pages 202 - 210, XP009134321 | [A] KRAJ MARIA: "Multiple myeloma bone disease and novel anti-myeloma agents", ACTA HAEMATOLOGICA POLONICA, vol. 39, no. 2, 2008, pages 163 - 178, XP009134337, ISSN: 0001-5814 | [A] DIARRA DANIELLE ET AL: "Dickkopf-1 is a master regulator of joint remodeling", NATURE MEDICINE, NATURE PUBLISHING GROUP, NEW YORK, NY, US LNKD- DOI:10.1038/NM1538, vol. 13, no. 2, 1 February 2007 (2007-02-01), pages 156 - 163, XP002486201, ISSN: 1078-8956, [retrieved on 20070121] DOI: http://dx.doi.org/10.1038/nm1538 | Examination | WO2010129752 | MLODY MAZON ET AL: "Modulating Dickkopf-1: A Strategy to Monitor or Treat Cancer?", CANCERS, vol. 8, no. 7, 28 June 2016 (2016-06-28), pages 62, XP055329263, DOI: 10.3390/cancers8070062 DOI: http://dx.doi.org/10.3390/cancers8070062 | by applicant | WO2006015373 | US4816397 | US5225539 | US5693761 | HARLOW; LANE: "Antibodies, A Laboratory Manual", 1988, COLD SPRING HARBOR LABORATORY PRESS | MARIE-PAULE LEFRANC; GERARD LEFRANC: "The Immunoglobulin FactsBook", 2001, ACADEMIC PRESS | QUEEN ET AL., PROC. NATL. ACAD. SCI. USA, vol. 88, 1991, pages 2869 | LEVITT, J. MOL. BIOL., vol. 168, 1983, pages 595 - 620 | JONES ET AL., NATURE, vol. 321, 1986, pages 522 - 525 | RIECHMANN ET AL., NATURE, vol. 332, 1988, pages 323 - 327 | VERHOEYEN ET AL., SCIENCE, vol. 239, 1988, pages 1534 - 1536 | WU ET AL., J. MOL. BIOL., vol. 294, 1999, pages 151 - 162 | HARLOW; LANE: "Antibodies, A Laboratory Manual", 1988, COLD SPRING HARBOR LABORATORY PRESS, pages: 567 - 569 | A. GENNARO ET AL.: "Remington: The Science and Practice of Pharmacy", 1995, MACK PUBLISHING CO. |